CholremCholesterol & arterial science

Cholrem Pty Ltd · Est. 2018 · Gold Coast, Australia

The molecule the world is waking up to. The human arterial data only one company holds.

Hydroxypropyl-beta-cyclodextrin (HPβCD) dissolves cholesterol. In November 2026 the US FDA approved it as a medicine for the first time. Cholrem has spent eight years turning that molecule against the world’s biggest killer through Cavadex®, its at-home HPβCD formulation, and holds the first human coronary imaging that shows what it can do.

  • 2018Established
  • 8 yrsHuman R&D
  • 6 + 1Papers published, one in peer review
  • 4,000+Users since 2020
  • PatentPending
November 2026

The molecule Cholrem has studied in humans since 2018 is now an FDA-approved medicine

HPβCD was licensed in the United States this month for a rare childhood disease, with more than a decade of high-dose intravenous human use behind it. Cholrem holds the only human cardiovascular data for it.

Read the news

Scientific convergence

Three forces are meeting in one molecule

Independent science, global biotech investment and eight years of Cholrem’s human translation are converging on HPβCD at the same moment.

1 · The world’s laboratories

The mechanism is proven and published

Cholesterol crystals and cholesterol-loaded cells drive atherosclerosis, and the same biology sits upstream of neurodegeneration. Labs at Bonn, Cornell and elsewhere have shown HPβCD dissolves the crystals, switches on the cell’s own cholesterol-export machinery and reprograms inflamed macrophages into healing ones.

The independent science →
2 · Global biotech

Serious money is moving

Beren raised US$300 million and won FDA approval for HPβCD in 2026. Cyclarity Therapeutics has FDA clearance to trial an engineered cyclodextrin in coronary artery disease. Rafael Holdings has filed an intravenous HPβCD drug application. The class is now real.

What is happening in the field →
3 · Cholrem

Cavadex®: the same molecule, in a form only Cholrem makes

Cavadex is HPβCD prepared by Cholrem’s own process into a high-viscosity formulation for nightly use at home. The molecule is unchanged. The preparation and delivery are Cholrem’s, and are the subject of its patent application. Eight years of human research, thousands of users, six published papers and the first coronary images of plaque regressing on HPβCD all came from it.

Why Cholrem leads →

Companies have raised tens to hundreds of millions of dollars chasing results Cholrem has already achieved in human arteries.

Beren raised US$300 million in 2026. Its patent filings on treating cardiovascular disease with cyclodextrins date from August 2020, more than a year after Cholrem’s public disclosure. Cyclarity begins its first coronary patient study in 2027. Neither has published human arterial imaging. Cholrem has, across its published papers.

CT coronary angiogram reconstructions, February 2024: LAD, RCA and circumflex arteries patent
CT coronary angiogram, February 2024. Eleven months earlier the same patient’s invasive angiogram showed 70–99% blockages in all three coronary arteries. He declined bypass surgery and all medication and used Cavadex nightly. Case report under peer review, 2026.

The data

Plaque that was supposed to be permanent

Medicine has treated established coronary plaque as irreversible for a century. Cholrem’s human imaging says otherwise: severe stenoses reduced on CT, calcium scores that stop rising and begin to fall, and symptom relief reported across an observational cohort of 125 people.

See the data

Cavadex®

The formulation behind the data

Every Cholrem paper, image and registry entry comes from people using Cavadex. It is pharmaceutical-grade HPβCD, the molecule the FDA has now approved, prepared by Cholrem’s own process into a high-viscosity formulation taken nightly at home. The molecule is unchanged. The preparation and the delivery are Cholrem’s, and are the subject of its patent application.

  • Active moleculeHydroxypropyl-beta-cyclodextrin, pharmaceutical grade
  • What is Cholrem’sThe production process, the high-viscosity formulation and the at-home route. Patent pending.
  • In human useSince 2020. The current Quad Strength generation delivers four times the HPβCD per unit dose of the original
  • Measured on itCoronary, carotid and peripheral plaque on CT and ultrasound, serial calcium scores, lipids, symptoms
  • PublishedSix papers, a case report in peer review and a member registry

The frontier

Cholesterol is the common thread. HPβCD pulls on it.

Coronary disease is the first program. The same mechanism points at every disease where cholesterol accumulates where it should not.

Coronary & systemic atherosclerosis

Human imaging data in hand: coronary, peripheral and carotid regression documented across Cholrem’s published case series.

Coronary artery calcification

Serial calcium scores falling on a scanner-matched basis, a result no drug class has produced in a controlled trial.

Peripheral arterial disease

Limb perfusion and walking distance in published cases. The potential to change outcomes for patients facing amputation.

Cognition & Alzheimer’s disease

Cornell showed HPβCD clears amyloid and restores memory in Alzheimer’s models. Cholrem’s users consistently report sharper thinking. Enormous potential, now being mapped.

Vascular & sexual function

Erectile function is a window on small-vessel health. User reports of improvement match the mechanism and open a large, unaddressed market.

Lipids & metabolic health

Serum cholesterol and triglycerides fall during treatment, observed across Cholrem’s papers and now a program in its own right.

Buy into the delivery key, not a single product

Cholrem offers partners the only human cardiovascular dataset for HPβCD, a patent-pending at-home formulation, an eight-year head start and a molecule whose reach across vascular and neurodegenerative medicine is only beginning to unfold.